Mercosur countries sign agreements on disease control
Mercosur Ministries of Health have recently signed seven agreements establishing integrated actions for the control and prevention of diseases, at a meeting in Brazil. Mercosur is an economic and political agreement signed in 1991 among Argentina, Brazil, Paraguay, Uruguay and Venezuela.
The documents aim to contribute to a reduction in the number of deaths and cases of leishmaniasis, tuberculosis, dengue fever, HIV/AIDS and chronic non-communicable diseases in the region.
Brazil’s Health Minister, Alexandre Padilha, highlighted the importance of the initiatives. "The Ministries of Health of full and associate member states in the block are undertaking innovative measures to further strengthen ties in order to improve the quality of health of their populations," he said.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze